Applies to the following strengths: 50 mg
Usual Adult Dose for Breast Cancer-Palliative
For use as adjunctive therapy in the palliative treatment of advanced or disseminated breast cancer in postmenopausal women when hormonal therapy is indicated or in women who were diagnosed as having had disseminated breast carcinoma when premenopausal, in whom ovarian function has been subsequently terminated: 250 mg 4 times a day.
In order to evaluate the response, therapy with testolactone should be continued for a minimum of 3 months unless there is active progression of the disease.
Testolactone is contraindicated for use in breast cancer in men.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.